Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …

Multi-drug resistance (MDR) developed in response to chemotherapy is one of the
prominent causes of therapeutic failure. The major underlying factors that contribute to such …

Oncogenic activation of fibroblast growth factor receptor 2 (FGFR2) drives multiple cancers
and represents a broad therapeutic opportunity, yet selective targeting of FGFR2 has not …

Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective
in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors …

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive primary liver malignancy with an
increasing incidence worldwide. Recently, histopathologic classification of small duct type …

Epidermal growth factor receptor (EGFR) is an anticancer drug target for a number of
cancers, such as non-small cell lung cancer. However, unsatisfying treatment effects, terrible …

Cholangiocarcinoma (CCA) is a type of highly malignant tumor originating from bile ducts.
The prognosis of CCA is poor and the treatment options are limited. The biomarker study of …

Abstract The US Food and Drug Administration has approved a total of 37 new drugs in
2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 …

Objective Fibroblast‐like synoviocytes (FLSs) contribute to inflammation and joint damage in
rheumatoid arthritis (RA). However, the regulatory mechanisms of FLSs in relapse and …

Long non-coding RNA (lncRNA) DANCR (also known as ANCR)—differentiation
antagonizing non-protein coding RNA, was first reported in 2012 to suppress differentiation …